The present invention relates to the treatment of cancer. Here, the inventors evaluated EAPB02303 effects in PDAC cell lines and mouse models and […]

Immunotherapy has transformed cancer treatment but often struggles with solid tumors due to immune resistance from the tumor microenvironment (TME). […]

Melanoma cell plasticity plays a key role in the acquisition of resistance to therapy. TRIM24/TIF1α, which encodes for the tripartite […]

The Inventors herein demonstrate that CD39 is a relevant therapeutic target in B-celllymphoma, in particular Follicular Lymphoma (FL), Diffuse Large […]

The cholangiocarcinoma cell line SB1-JP4 is syngeneic to C57Bl/6 mice.It was derived from a tumor formed by SB1 cells in C57Bl/6 mice, then harvested, […]

PTLDs arise after solid organ and hematopoietic stem cell transplants, with occurrences linked to immunosuppressive therapy and EBV status. Initial […]

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker in cancer. The inventors aim to assess the dynamic evolution of ctDNA in patients […]

The present invention relates to the treatment of brain or neurologic disorders. In this study, the inventors hypothesized that a Fc receptor (FcRn) […]

The present invention relates to a method for predicting the survival time and/or the disease severity in a subject suffering from a disease […]

Familial adenomatous polyposis (FAP) patients harbor mutations in the APC gene and will develop adenoma and early colorectal cancer. Taking biopsies […]